Kiniksa Pharmaceuticals (NASDAQ:KNSA) Earns Outperform Rating from Wedbush

Kiniksa Pharmaceuticals (NASDAQ:KNSA)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a research report issued to clients and investors on Tuesday, RTT News reports. They presently have a $30.00 price target on the stock. Wedbush’s price target indicates a potential upside of 66.20% from the stock’s current price.

Separately, TheStreet upgraded Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research report on Thursday, February 29th.

Kiniksa Pharmaceuticals Stock Up 5.6 %

NASDAQ:KNSA traded up $0.96 on Tuesday, reaching $18.05. 277,727 shares of the company’s stock traded hands, compared to its average volume of 398,369. The stock has a 50-day simple moving average of $19.40 and a 200-day simple moving average of $18.00. The firm has a market cap of $1.27 billion, a PE ratio of 100.28 and a beta of 0.27. Kiniksa Pharmaceuticals has a 12 month low of $10.65 and a 12 month high of $22.09.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.15. The business had revenue of $83.40 million for the quarter, compared to analysts’ expectations of $72.31 million. Kiniksa Pharmaceuticals had a negative return on equity of 6.12% and a net margin of 5.11%. On average, equities analysts anticipate that Kiniksa Pharmaceuticals will post -0.06 earnings per share for the current year.

Insider Activity

In other news, CAO Michael R. Megna sold 5,126 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total transaction of $111,695.54. Following the completion of the transaction, the chief accounting officer now owns 17,588 shares in the company, valued at $383,242.52. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Sanj K. Patel sold 12,742 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $21.49, for a total value of $273,825.58. Following the completion of the transaction, the chief executive officer now owns 70,594 shares in the company, valued at $1,517,065.06. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Michael R. Megna sold 5,126 shares of Kiniksa Pharmaceuticals stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total value of $111,695.54. Following the completion of the transaction, the chief accounting officer now owns 17,588 shares of the company’s stock, valued at approximately $383,242.52. The disclosure for this sale can be found here. Insiders sold a total of 33,109 shares of company stock worth $709,929 over the last 90 days. Corporate insiders own 54.23% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tejara Capital Ltd boosted its position in shares of Kiniksa Pharmaceuticals by 3.2% during the third quarter. Tejara Capital Ltd now owns 35,000 shares of the company’s stock valued at $608,000 after buying an additional 1,069 shares during the period. Los Angeles Capital Management LLC boosted its position in shares of Kiniksa Pharmaceuticals by 1.1% during the fourth quarter. Los Angeles Capital Management LLC now owns 147,182 shares of the company’s stock valued at $2,582,000 after buying an additional 1,540 shares during the period. QRG Capital Management Inc. boosted its position in shares of Kiniksa Pharmaceuticals by 11.7% during the fourth quarter. QRG Capital Management Inc. now owns 16,010 shares of the company’s stock valued at $281,000 after buying an additional 1,679 shares during the period. Profund Advisors LLC boosted its position in shares of Kiniksa Pharmaceuticals by 7.8% during the third quarter. Profund Advisors LLC now owns 23,506 shares of the company’s stock valued at $408,000 after buying an additional 1,700 shares during the period. Finally, Deutsche Bank AG boosted its position in shares of Kiniksa Pharmaceuticals by 2.5% during the third quarter. Deutsche Bank AG now owns 91,726 shares of the company’s stock valued at $1,593,000 after buying an additional 2,220 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.